SSY GROUP (02005.HK): 95 Varieties Included in National Essential Medicines List (2026 Edition)
NewTimeSpace News: SSY GROUP (02005.HK) announced that a total of 95 varieties (141 specifications) of the Group’s products have been incorporated into the National Essential Medicines List (2026 Edition), including 32 newly added varieties (37 specifications). The catalogue will take effect on 1 September 2026 and is expected to exert a positive impact on the Group’s growth and business development.
NewTimeSpace News: On 10 July 2026, SSY GROUP (02005.HK) released a voluntary announcement. Altogether 95 varieties (141 specifications) of the Group’s products are included in the National Essential Medicines List (2026 Edition), among which 32 varieties (37 specifications) are newly added. The products cover Glucose and Sodium Chloride Injection, Levofloxacin Sodium Chloride Injection, Sodium Bicarbonate Injection, Fluconazole Tablets, Gliclazide Tablets, Potassium Chloride Injection, Mecobalamin Injection, Azithromycin Dry Suspension and others.
The National Essential Medicines List (2026 Edition) shall be implemented on 1 September 2026. It is expected to bring positive impacts on the Group’s growth and business development.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- SSY GROUP (02005.HK): Obtains production registration approval for sodium ozagrel injection, achieving full dosage form coverage
- SSY GROUP (02005.HK): Vitamin K1 Injection obtains NMPA drug production registration certificate, deemed to pass consistency evaluation
- SSY GROUP (02005.HK): Four Products Receive NMPA Drug Manufacturing Registration Approvals, Deepening Infusion Therapy and Ophthalmology Portfolio
- SSY Group (02005.HK): All 16 Specifications of 13 Pharmaceutical Varieties Proposed to Be Selected in the 12th National Centralized Drug Procurement
- SSY Group (02005.HK): Cimetidine Injection and Acetylcysteine Solution for Inhalation Obtain Manufacturing Registration Approvals
